The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
about
Allopurinol for chronic goutFebuxostat for treating chronic goutFebuxostat for treating chronic gout2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaLesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinolTreatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsFebuxostatAssociations Between Hyperuricemia and Chronic Kidney Disease: A ReviewUric acid and chronic kidney disease: which is chasing which?Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisalGouty Arthritis: A Review of Acute Management and Prevention.Treatment approaches and adherence to urate-lowering therapy for patients with gout.Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up studyUric acid as one of the important factors in multifactorial disorders--facts and controversies.Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndromeAfrican American patients with gout: efficacy and safety of febuxostat vs allopurinol.Efficacy and safety of febuxostat in elderly female patients.The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.2011 recommendations for the diagnosis and management of gout and hyperuricemia.Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease[The etiology and management of gout].The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortalityCanakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.An update on the pathology and clinical management of gouty arthritis.Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.Efficacy and safety of febuxostat in patients with hyperuricemia and gout.Uric acid as a target of therapy in CKD.Prophylaxis on gout flares after the initiation of urate-lowering therapy: a retrospective research.Latest evidence on gout management: what the clinician needs to knowChronic hyperuricemia, uric acid deposit and cardiovascular riskThe effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.Predicting allopurinol response in patients with gout2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare systemDisease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective AnalysisComparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysisRandomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones
P2860
Q24193107-B9221B31-2454-4A78-A932-7EA2BBDD6FDBQ24202984-E089D8B2-0A75-4C22-A3B0-85516CB5DED5Q24236637-13F14FD2-F4A3-46DB-8B78-824E9160D27AQ24612292-7D39817C-D9A8-43E6-AF70-3C230D8A5C3EQ24658504-34D123BD-6D31-404A-8085-F5AFCEAB1445Q26738948-AEF7288A-986A-4770-B096-9784F81E559CQ26773263-AACC5136-B5B2-4B57-82E7-2EF6A8DB8F1CQ26796333-2DE7DD27-3B75-4B06-B870-E3115C05870CQ26824554-6F1EB181-31C1-40F9-917D-F869F4075F44Q26862468-5A5C2722-24C4-46C0-AF8C-2153FEAF378DQ30249531-CEF07187-0857-4735-A659-58AECE7C8CEFQ33597442-BCDE6A04-B82C-4DA4-ACC8-F5BCD6BA46FBQ33706623-E5A6EA26-152E-4127-85CC-E7F8038F604FQ33773142-268040C7-A402-48E9-A760-ACDCA8C81BFFQ34141630-38510806-69D1-45F9-A80E-74EE10C21D7BQ34153554-C43985FD-628B-497A-B1F6-B409DDE74B7CQ34154666-D40029E9-6BBF-4507-B9D2-DB8237CC2827Q34204854-645125B7-706B-40EC-AA65-8B405CD8AEB1Q34250995-2DD253D8-9467-404C-8C0E-08F6E83FF51BQ34317722-98E2A2C6-B544-4EF5-88C9-78AB60F4884CQ34636225-2F9C4914-4AC7-4EB3-A7DC-28205F2C88FFQ34877729-6228C423-0365-4AB4-9A72-B8B8A9BD6F77Q35012174-0EF10FF6-1CBF-4255-899F-84160E1B2625Q35528880-5BA48636-A665-4C5C-B70A-EFD79F4416BCQ35643985-32B07809-6B4E-4BD0-B092-C9074E960E73Q35775875-613BE748-7CB7-424E-AA5B-4751F463AB37Q36059557-B5038E89-D0F2-4ED7-A71C-9E5745BC01CDQ36476464-D39D5582-5A53-46C8-88D5-299882717E11Q36493145-CAAEE43D-C192-4C7F-A6D5-91787AF09A44Q36515484-8E2182D0-1209-4D41-9524-A48757C53830Q36712438-085CDAB4-C095-4D7A-93E6-D6B4461B4D15Q36779141-8E49459F-8A7B-4E20-8FB3-FEA8848A7563Q36802064-69AEB79F-E42D-4EA7-AA3C-D329E890A1C5Q36870924-E538B07A-15F4-402B-BB07-97E0B583DD8AQ36903272-67C36262-6B41-4224-B069-83CA45157142Q36981450-562373E4-EE17-48D4-85DE-20BE6A7D1923Q37041741-B2B45C83-DB23-4E0F-B164-3CD01E41F0F8Q37208467-22FE7373-FA56-4031-97E9-A577A96CD66FQ37240086-0D0D77DF-B6C5-4339-8F13-B68138C4E7DAQ37280815-77EEE2EE-729A-47B6-92D5-5DCFC87A2EDB
P2860
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@ast
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en-gb
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@nl
type
label
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@ast
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en-gb
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@nl
prefLabel
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@ast
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en-gb
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@nl
P2093
P2860
P3181
P356
P1476
The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial
@en
P2093
Alvin F Wells
Christopher Lademacher
Eric Lloyd
H Ralph Schumacher
Luis R Espinoza
Michael A Becker
Patricia MacDonald
P2860
P2888
P3181
P356
10.1186/AR2978
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1042889871